Inhibitors of the GPIb-vWF interaction, their preparation and use
View Patent ↗The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, E, n, m or o have the meanings indicated below. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases.
1. A compound of the formula I,
wherein
n is the integer zero, 1, 2, 3 or 4;
m is the integer zero, 1, 2, 3 or 4;
o is the integer zero, 1, 2, 3 or 4;
R1 is —(C 1 -C 8 )-alkyl;
R2 is —NR 4 R 5 , wherein
R 4 and R 5 are identical or different and are hydrogen atom or —(C 1 -C 8 )-alkyl;
A is —CO—NH—;
B is 1. a covalent bond,
2. a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 ,
3. (C 3 -C 8 )-cycloalkyl or
4. Het, wherein Het is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 ,
D is —NH—;
E is Het, wherein Het is a saturated, partially unsaturated or aromatic monocyclic or bicyclic heterocyclic ring system containing 3 to 10 ring atoms of which 1, 2, 3 or 4 are identical or different heteroatoms selected from the series consisting of nitrogen, oxygen and sulfur and wherein Het is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 ;
with the proviso that, when B is a covalent bond and Het is a bicyclic heterocyclic ring system, the ring of Het to which D-(CH 2 ) o — is attached contains at least one hetero atom;
R 3 is 1. —(C 1 -C 8 )-alkyl,
2. (C 1 -C 8 )-alkoxy,
3. hydroxyl,
4. trifluoromethoxy,
5. trifluoromethyl,
6. halogen,
7. nitro,
8. —NR 4 R 5 , wherein R 4 and R 5 are as defined above,
9. —(C 1 -C 8 )-alkylcarbonyl,
10. —CN,
11. aminosulfonyl-,
12. amidino,
13. guanidino,
14. tri-((C 1 -C 4 )-alkyl)ammonio-,
15. di-((C 1 -C 8 )-alkyl)amino-,
16. (C 1 -C 8 )-alkylaminosulfonyl-,
17. di-((C 1 -C 8 )-alkyl)aminosulfonyl,
18. —O-Het, wherein Het is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 and R 3 is as defined above under 1. to 17., or
19. Het-, wherein Het is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 and R 3 is as defined above under 1. to 17.,
in all their stereoisomeric forms and their physiologically tolerable salts.
2. A compound of the formula I,
wherein
n is the integer zero, 1, 2, 3 or 4;
m is the integer zero, 1, 2, 3 or 4;
o is the integer zero, 1, 2, 3 or 4;
R1 is —(C 1 -C 8 )-alkyl;
R2 is —NR 4 R 5 , wherein
R 4 and R 5 are identical or different and are hydrogen atom or —(C 1 -C 8 )-alkyl;
A is —CO—NH—;
B is 1. a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 ,
2. (C 3 -C 8 )-cycloalkyl or
3. Het, wherein Het is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 ,
D is —NH—;
E is Het, wherein Het is a saturated, partially unsaturated or aromatic monocyclic or bicyclic heterocyclic ring system containing 3 to 10 ring atoms of which 1, 2, 3 or 4 are identical or different heteroatoms selected from the series consisting of nitrogen, oxygen and sulfur and wherein Het is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 ;
with the proviso that, when B is a covalent bond and Het is a bicyclic heterocyclic ring system, the ring of Het to which D-(CH 2 ) o — is attached contains at least one hetero atom;
R 3 is 1. —(C 1 -C 8 )-alkyl,
2. (C 1 -C 8 )-alkoxy,
3. hydroxyl,
4. trifluoromethoxy,
5. trifluoromethyl,
6. halogen,
7. nitro,
8. —NR 4 R 5 , wherein R 4 and R 5 are as defined above,
9. —(C 1 -C 8 )-alkylcarbonyl,
10. —CN,
11. aminosulfonyl-,
12. amidino,
13. guanidino,
14. tri-((C 1 -C 4 )-alkyl)ammonio-,
15. di-((C 1 -C 8 )-alkyl)amino-,
16. (C 1 -C 8 )-alkylaminosulfonyl-,
17. di-((C 1 -C 8 )-alkyl)aminosulfonyl,
18. —O-Het, wherein Het is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 and R 3 is as defined above under 1. to 17., or
19. Het-, wherein Het is unsubstituted or mono-, di-, tri- or tetrasubstituted independently of one another by R 3 and R 3 is as defined above under 1. to 17.,
in all their stereoisomeric forms and their physiologically tolerable salts.
3. A compound of the formula I, as claimed in claim 1 , wherein
n is the integer zero or 1,
m is the integer zero or 1,
o is the integer zero or 1,
R1 is —(C 1 -C 4 )-alkyl;
R2 is —NR 4 R 5 , wherein
R 4 and R 5 are identical or different and are hydrogen atom or —(C 1 -C 4 )-alkyl;
A is —CO—NH—;
B is 1. a covalent bond,
2. a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R 3 , or
3. (C 3 -C 7 )-cycloalkyl,
D is —NH—;
E is Het selected from the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,4-dioxine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, benzo[1,4]dioxine, 4H-benzo[1,4]oxazine, indazole, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, chromane, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pyridoimidazoles, pyridopyridines, pyridopyrimidines or ring systems which result from the listed heterocycles by fusion or condensation of a carbocyclic ring, for example benzo-fused, cyclopenta-fused, cyclohexa-fused or cyclohepta-fused derivatives of these heterocycles, pyrroline, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine morpholine), 2,3-dihydrobenzo[1,4]dioxine, indoline, isoindoline, 3,4-dihydro-2H-benzo[1,4]oxazine, perhydro-1,4-thiazine, perhydroazepine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline and wherein Het is unsubstituted or mono-, di- or trisubstituted independently of one another by R 3 ;
R 3 is 1. —(C 1 -C 4 )-alkyl,
2. hydroxyl,
3. halogen,
4. —NR 4 R 5 , wherein R 4 and R 5 are as defined above,
5. aminosulfonyl-,
6. (C 1 -C 8 )-alkylaminosulfonyl-,
7. di-((C 1 -C 8 )-alkyl)aminosulfonyl,
8. —(C 1 -C 8 )-alkoxy,
9. —O-Het, wherein Het is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R 3 and R 3 is as defined above under 1. to 8., or
10. Het-, wherein Het is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R 3 and R 3 is as defined above under 1. to 8.
4. A compound of the formula I as claimed in claim 1 or 2 , wherein
n is the integer zero or 1,
m is the integer zero or 1,
o is the integer zero or 1,
R1 is methyl;
R2 is amino;
A is —CO—NH—;
B is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R 3 ,
D is —NH—;
E is Het, which is selected from the group pyridine, pyrimidine, pyrazine, quinoline, benzimidazole, benzothiazole, isoquinoline, chromane, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pyridoimidazoles, pyrroline, pyrrolidine, tetrahydropyridine, indazole, piperidine, imidazolidine, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, piperazine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline and wherein Het is unsubstituted or mono-, di- or trisubstituted independently of one another by R 3 ;
R 3 is 1. methyl,
2. hydroxyl,
3. halogen,
4. —NH 2 ,
5. aminosulfonyl-,
6. methoxyl,
7. —O-Het, wherein Het is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R 3 and R 3 is as defined above under 1. to 6., or
8. Het-, wherein Het is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R 3 and R 3 is as defined above under 1. to 6.
5. A compound of the formula I as claimed in claim 1 , wherein the compound of the formula I is
2-Amino-4-[(4-{[(4-amino-2-methyl-6-quinolinyl)carbonyl]amino}phenyl)amino]-1,6-dimethylpyrimidin-1-ium,
2-Amino-4-[(3-{[(4-amino-2-methyl-6-quinolinyl)carbonyl]amino}phenyl)amino]-1,6-dimethylpyrimidin-1-ium,
2-Amino-4-[(4-{[(4-amino-2-methyl-6-quinolinyl)carbonyl]amino}benzyl)amino]-1,6-dimethylpyrimidin-1-ium,
2-Amino-4-[(4-{[(4-amino-2-methyl-6-quinolinyl)carbonyl]amino}benzyl)amino]-6-methylpyrimidine, or
4-Amino-N-{4-[(1H-indazol-6-ylamino)methyl]phenyl}-2-methyl-6-quinolinecarboxamide.
6. A process for the preparation of a compound of the formula I as claimed in claim 1 or 2 , which comprises linking the building blocks of the formulae II, III, and IV
by means of forming in a manner known per se an amide bond between the carboxylic acid group G1 depicted in formula II and the NH 2 group G2 depicted in formula III or between the carboxylic acid group G2 depicted in formula III and the NH 2 group G1 depicted in formula II and
by means of forming a bonding between building block of the formula III and building block of the formula IV by nucleophilic substitution of an halogen atom G4 depicted in formula IV by an amino group G3 depicted in formula III or
by means of forming a bonding between building block of the formula III and building block of the formula IV by nucleophilic substitution of an halogen atom G3 depicted in formula III by an amino group G4 depicted in formula IV.
7. A pharmaceutical preparation, comprising at least one compound of the formula I as claimed in claim 1 or 2 in all its stereoisomeric forms and mixtures thereof in any ratio and/or its physiologically tolerable salts and a pharmaceutically acceptable carrier.